Thermon Group Holdings News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.05.17	ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary (PR Newswire)
11.05.17	ThromboGenics Business Update - Q1 2017 (PR Newswire)
11.05.17	ThromboGenics Business Update - Q1 2017 (PR Newswire)
02.05.17	New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore (PR Newswire)
02.05.17	New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore (PR Newswire)
20.04.17	ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema (PR Newswire)
20.04.17	ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema (PR Newswire)
16.03.17	ThromboGenics Business Update - FY 2016 (PR Newswire)
16.03.17	ThromboGenics Business Update - FY 2016 (PR Newswire)
10.01.17	ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME) (PR Newswire)
10.01.17	ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME) (PR Newswire)
07.04.15	Thermon Reveals Acquisition Of Sumac (RTTNews)
23.12.14	Thermon Agrees To Buy Unitemp (RTTNews)
29.05.14	Thermon Profit Rises On Lower Expenses, Yet Misses Street (RTTNews)
23.10.13	National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics' JETREA® for Treatment of a Broad Range of Patients with Vitreomacular Traction (VMT),... (PR Newswire)
23.10.13	National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics' JETREA® for Treatment of a Broad Range of Patients with Vitreomacular Traction (VMT),... (PR Newswire)
21.10.13	ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA (PR Newswire)
21.10.13	ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA (PR Newswire)
17.10.13	Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole (PR Newswire)
17.10.13	Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole (PR Newswire)
01.10.13	Euretina Presentation "Adoption of JETREA® in My Everyday Practice" Confirms Need for a New Paradigm in Treatment of Symptomatic VMA/ VMT, Including Those Cases Associated with MH (PR Newswire)
01.10.13	Euretina Presentation "Adoption of JETREA® in My Everyday Practice" Confirms Need for a New Paradigm in Treatment of Symptomatic VMA/ VMT, Including Those Cases Associated with MH (PR Newswire)
30.09.13	ThromboGenics Establishes Level 1 ADR Program for US Investors (PR Newswire)
30.09.13	ThromboGenics Establishes Level 1 ADR Program for US Investors (PR Newswire)
05.09.13	ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema (PR Newswire)
05.09.13	ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema (PR Newswire)
02.09.13	UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA® for Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
02.09.13	UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA® for Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
29.08.13	ThromboGenics Business Update H1 2013 (PR Newswire)
29.08.13	ThromboGenics Business Update H1 2013 (PR Newswire)
23.08.13	Thermon Holding Corp. -- Moody's withdraws all ratings for Thermon Holding Corp. (Moodys)
16.08.13	Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion (PR Newswire)
16.08.13	Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion (PR Newswire)
02.08.13	Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
02.08.13	Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.38	1.88 %	K V
UBS Group	28.01	1.23 %	K V
Part Grp Hldg	1’265.50	0.92 %	K V
Geberit	527.20	0.65 %	K V
ABB	49.33	0.63 %	K V
Lonza Grp	516.20	-0.15 %	K V
Nestle	76.20	-0.21 %	K V
CieFinRichemont	121.25	-0.53 %	K V
Sonova Hldg	301.30	-0.89 %	K V
Givaudan	3’840.00	-1.03 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Thermon Group Holdings Inc.

Aktien Top/Flop

Meistgelesene Nachrichten